Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ARN19702 is a selective, orally active, reversible, and brain-penetrant N-acylethanolamine acid amidase (NAAA) inhibitor with an IC 50 of 230 nM for human NAAA. ARN19702 exhibits a broad analgesic profile [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 51.00 | |
5 mg | In stock | $ 122.00 | |
10 mg | In stock | $ 197.00 | |
25 mg | In stock | $ 389.00 | |
50 mg | In stock | $ 622.00 | |
100 mg | In stock | $ 978.00 | |
200 mg | In stock | $ 1,320.00 | |
500 mg | In stock | $ 1,960.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 133.00 |
Description | ARN19702 is a selective, orally active, reversible, and brain-penetrant N-acylethanolamine acid amidase (NAAA) inhibitor with an IC 50 of 230 nM for human NAAA. ARN19702 exhibits a broad analgesic profile [1] [2]. |
Targets&IC50 | NAAA:230 nM |
In vivo | ARN19702, administered orally (po) at dosages of 3-10 mg/kg daily for seven consecutive days, effectively reduces Paclitaxel-induced neuropathic nociception in male rats without causing subacute antinociceptive tolerance [1]. In male mice, ARN19702 demonstrates a dose-dependent reduction in spontaneous nocifensive behaviors triggered by intraplantar formalin, and alleviates hypersensitivity following intraplantar carrageenan injection, paw incision, or sciatic nerve ligation, at dosages ranging from 0.1-30 mg/kg (po) [1]. Additionally, at a dosage range of 3-10 mg/kg (po), ARN19702 offers significant protection against multiple sclerosis in mice [2]. Pharmacokinetic analysis in mice reveals that at a 3 mg/kg dosage, ARN19702 achieves a maximum concentration (Cmax) of 1660±166 ng/mL and 613±68 ng/mL for intravenous (i.v.) and oral administration respectively, with corresponding times to reach Cmax (Tmax) of approximately 5.0 minutes (i.v.) and 30 minutes (po). The clearance (CL) rates stand at 33.2±1.6 mL/min/kg (i.v.) and 49±8 mL/min/kg (po), with half-lives (t 1/2) of 73.9±3.7 minutes (i.v.) and 104±16 minutes (po). Area under the curve (AUC) measurements indicate plasma levels of 1366.8±68.3 h×ng/mL (i.v.) and 988±157 h×ng/mL (po), and brain levels of 404.3±109.1 h×ng/mL (i.v.) and 181±28 h×ng/mL (po), with an oral bioavailability (F) of 72±11%. |
Molecular Weight | 447.55 |
Formula | C21H22FN3O3S2 |
CAS No. | 1971937-18-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (111.72 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ARN19702 1971937-18-4 Others ARN 19702 ARN-19702 inhibitor inhibit